1. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma 
Mauricette Michallet, Thierry Philip, Irène Philip, Hubert Godinot, Catherine Sebban, Gilles Salles, Anne Thiebaut, Pierre Biron, Francis Lopez, Philippe Mazars, Nora Roubi, Tom Leemhuis, Elie Hanania, Christopher Reading, Gilbert Fine, Kerry Atkinson, Chris Juttner, Bertrand Coiffier, Denis Fière, Eric Archimbaud 
Experimental Hematology 
Volume 28, Issue 7, Pages (July 2000)
DOI: /S X(00)

2. Figure 1
Schema of study design. Patients were mobilized with granulocyte-macrophage colony-stimulating factor (GM-CSF) and cyclophosphamide. Peripheral blood mononuclear cells (PBMC) were collected and CD34+Thy1+cells selected using a two-step process. For safety concerns with this new source of cells, the first cohort of patient recieved melphalan alone as conditioning regimen followed by CD34+Thy1+ infusion. Subsequent patient cohorts received melphalan + total body irradiation (TBI) and decreasing numbers of CD34+Thy1+ cells. Progression from cohort 1 to 4 was based on the demonstration of sustained engraftment and adequate safety in the current cohort. The fifth cohort was added after considering poor engraftment results with the low CD34+Thy1+ cell dose cohorts. All patients received G-CSF after transplant and were followed-up 1 year after transplant
Experimental Hematology  , DOI: ( /S X(00) )

3. Figure 2
Neutrophil and platelet engraftment after transplant (median values) for melphalan + total body irradiation (TBI) regimen. Gray areas represent normal laboratory ranges
Experimental Hematology  , DOI: ( /S X(00) )

4. Figure 3
T-cell subset kinetics after transplant (median values). Gray areas represent normal laboratory ranges
Experimental Hematology  , DOI: ( /S X(00) )